A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- SURMOUNT-MMO
- status
- ACTIVE_NOT_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 15374
- sponsor
- Eli Lilly and Company
- conditions
- Obesity; Overweight
- interventions
- DRUG: Tirzepatide; DRUG: Placebo
- start date
- 2022-10-11
- start date type
- ACTUAL
- primary completion date
- 2027-10-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05556512
- Published
- Sep 27, 2022
- Updated
- Oct 7, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05556512
- Categories
- Obesity, Overweight
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials